Tyra Biosciences (TYRA) Q3 2026 earnings review
Tyra Biosciences clears bladder tumours, while new funding covers trials
Tyra Biosciences proved its lead cancer pill can clear early-stage bladder tumours while raising the cash to fund late-stage trials. In its Phase 2 study, a 60 mg daily dose of dabogratinib eliminated tumours in 64% of evaluated bladder cancer patients without severe treatment-related side effects. Chief executive Todd Harris raised $400 million in September to lift total cash to $701 million, even as quarterly operating expenses climbed 67% from a year ago.
| SURF302 60 mg complete response rate | 64% 75% in single-lesion bladder cancer patients |
|---|---|
| Cash and marketable securities | $700.5M up from $353.9M last quarter after $400M financing |
| Quarterly net loss | $51.1M +71% from a year ago as R&D jumped 69% |
| Cash runway outlook | Raised through 2030, up from second half of 2028 |
⚖️ Verdict: 🟢 Bullish
The story got better because the bladder cancer results validated the drug's clean safety profile and allowed the biotech to extend its cash runway through 2030. First complete tumour clearance in an upper tract cancer patient also showed the pill works in a second disease. One caution: the company reported bladder efficacy on only 14 of 44 safety patients, opened a higher 70 mg cohort, and pushed its children's growth readout deeper into 2027 after adding a sixth dose level.
The question now is whether dabogratinib's tumour clearance lasts long enough to win regulatory backing for a Phase 3 bladder trial and whether the sixth dose in children translates clean safety into competitive height gains. Either the 2027 readouts confirm durable efficacy across all three diseases, or dosing adjustments slow the path to approval. Health authority feedback on the Phase 3 bladder design and the six-month child growth numbers in 2027 will settle it.
🐂 Bull Case
Bladder Cancer Pill Cleared Tumours Without Typical Side Effects
Tyra Biosciences is testing dabogratinib, a daily pill that blocks a cancer-driving protein called FGFR3, in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). Patients with this early-stage cancer usually undergo repeated surgeries to scrape out tumours. Chief executive Todd Harris wants the pill to break that cycle.
In the SURF302 Phase 2 study, the 60 mg daily dose shrank or cleared tumours in most evaluated patients while avoiding the side effects that limit older FGFR drugs, "with no clinically significant hyperphosphatemia, nail toxicity or ocular toxicity observed".
- All evaluated 60 mg patients (14 people): 79% overall response rate and 64% complete tumour clearance
- Patients with a single tumour lesion (8 people): 100% response rate and 75% complete clearance
- Safety across both doses (44 people): zero severe Grade 3 treatment-related side effects at 60 mg
Clean safety matters because urologists will not prescribe a toxic pill for a non-fatal bladder condition. The results give the California biotech a path to a late-stage Phase 3 trial.
What to watch: health authority feedback and the start of the Phase 3 adjuvant bladder cancer trial in 2027. A green light from regulators would confirm that the 60 mg dose is ready for late-stage testing.
New Stock Sale Extends Cash Runway Through 2030
Developing one drug across three separate diseases requires hundreds of millions of dollars before any product revenue arrives. In September 2026, Tyra Biosciences raised about $400 million in gross proceeds by selling common stock and pre-funded warrants in a public offering led by RA Capital Management.
That followed $147.9 million in net proceeds raised through an at-the-market stock sale program in the first quarter. Total cash, cash equivalents and marketable securities reached $700.5 million on September 30, up from $353.9 million in June and $274.9 million a year ago.
By our math, the balance sheet grew by $346.6 million in the third quarter after covering roughly $44.4 million in operating cash burn and offering fees. Management extended its cash runway target by two years, from the second half of 2028 to through 2030, so the drug developer can run all three clinical programs without near-term funding pressure.
What to watch: quarterly cash burn in 2027 once the Phase 3 bladder trial begins. By our math, lasting 17 quarters through 2030 allows an average burn of $41.2 million per quarter.
First Upper Tract Cancer Patient Had a Complete Response
Low-grade upper tract urothelial carcinoma (LG-UTUC) is a tumour of the kidney lining and ureter where FGFR3 mutations drive about 85% of cases. The US company is running SURF303, a Phase 2a/b clinical trial designed to support regulatory approval, testing 60 mg and 80 mg daily doses of dabogratinib.
In September, Tyra Biosciences reported that the first patient treated in SURF303 achieved a complete response at the three-month checkup on the 60 mg dose, with zero treatment-emergent side effects as of the August 31 cutoff. A single patient does not prove a drug works, but clearing a tumour in the upper urinary tract confirms the pill reaches that tissue at an active level.
What to watch: additional Phase 2 clinical results from SURF303 in 2027. Consistent tumour clearance across a larger group of patients would make upper tract cancer a second registrational path alongside bladder cancer.
🐻 Bear Case
Bladder Trial Still Needs a Higher Dose and Pivotal Plan
Harris said "we believe the opportunity for a highly selective, oral FGFR3 inhibitor has never been clearer" after reporting the SURF302 bladder cancer readout. Yet the earnings release gave efficacy numbers for only 14 patients on the 60 mg dose out of 44 safety patients across both cohorts, and omitted response rates for the 50 mg group.
Two other actions show the dosing and clinical settings are still in flux. First, Tyra Biosciences opened a higher 70 mg daily cohort "to further explore oral dabogratinib's potential in the ablative setting", where the pill itself dissolves existing tumours. Second, while SURF302 tested that tumour-shrinking setting, management plans to run the Phase 3 trial in the adjuvant setting, where surgery removes the tumour first and the pill prevents its return.
Moving to an adjuvant trial aligns with the 75% complete response rate seen in the eight patients with a single lesion, but it means the company has not yet tested the exact Phase 3 setting or finished testing its highest ablative dose.
What to watch: results from the 70 mg ablative cohort and the final Phase 3 trial design in 2027. If regulators require longer follow-up or a larger trial for an adjuvant claim, timelines will stretch.
Children's Growth Trial Pushed Into 2027 on Sixth Dose
BEACH301 is a Phase 2 trial testing dabogratinib in children ages 3 to 10 with achondroplasia, the most common form of dwarfism. Across the past three quarters, Tyra Biosciences has repeatedly pushed back the timeline for the initial readout of six-month annualized height velocity and safety from roughly 25 children.
- Q4 2025 outlook: interim results expected in the second half of 2026
- Q1 2026 outlook: initial results expected in the fourth quarter of 2026
- Q2 2026 outlook: initial results expected by the end of the first quarter of 2027 after adding a fifth dose (0.625 mg/kg)
- Q3 2026 outlook: initial results expected in 2027 after adding a sixth dose (0.875 mg/kg)
Following clean safety across the first five doses, "the Data Safety Monitoring Committee authorized the opening of a sixth dose level to evaluate 0.875 mg/kg in the safety sentinel cohort". Higher dosing could improve child growth rates, because no severe safety issues have stopped the escalation, but every added dose level delays the efficacy proof.
What to watch: six-month annualized height velocity across all six dose levels in 2027. A clear dose response without FGFR3 toxicity would justify the extra time spent climbing to the sixth level.
Trial Spending Accelerated Before Phase 3 Even Starts
Running three Phase 2 clinical trials at the same time is driving a sharp climb in quarterly spending. Total operating expenses rose 66.6% from a year ago and 12.0% from last quarter to $54.9 million, pushing the third-quarter net loss to $51.1 million compared to $29.9 million a year earlier.
Research and development — the cost of running clinical trials and laboratory work — jumped 69.4% from a year ago to $43.1 million, making up 78.6% of total operating expenses, Tyra Biosciences reported. General and administrative expenses — executive pay and office overhead — climbed 57.1% to $11.7 million as the drug developer hired more staff.
That spending rate translates to nearly $220 million a year in operating expenses even before the company opens its first Phase 3 bladder cancer study in 2027.
What to watch: quarterly research and development expenses in early 2027. If quarterly operating costs climb past $60 million as Phase 3 starts, the cash buffer will face heavier pressure before 2030.
👓 Other Themes
Three-Disease Strategy Keeps the Pipeline Focused
In late 2025, Tyra Biosciences exited metastatic bladder cancer to concentrate its money on three indications for dabogratinib: intermediate-risk bladder cancer, upper tract urothelial cancer, and achondroplasia. The biotechnology group also owns two earlier drugs — TYRA-430 for liver cancer and TYRA-200 for bile duct cancer — alongside its SNÅP drug discovery platform, but the third-quarter release gave no clinical data or timelines for those programs.
💲 Other KPIs
Share count rose 15.8% from a year ago and 4.7% from last quarter to 69.1 million. Because the $400 million stock and pre-funded warrant offering closed in September, only part of the new shares entered the third-quarter average. That dilution kept net loss per share growth to 48.0% ($0.74 vs $0.50) even as net loss rose 71.2%.
Short-term obligations for clinical trial work and employee compensation climbed 19.0% from last quarter and 57.6% from $16.4 million at the end of 2025. Accounts payable also rose 41.4% from June to $3.3 million. Rising accrued liabilities mean some of the third quarter's $54.9 million operating expense has not yet left the bank account as cash.
Earnings on cash and marketable securities rose 22.3% from a year ago and 9.2% from last quarter to $3.8 million, reversing a first-half decline as stock sales rebuilt the cash balance.With $700.5 million on the balance sheet at quarter end, interest income will offset a larger slice of quarterly operating expenses starting in the fourth quarter.
🔮 Guidance
Raised. Following the $400 million September financing, the US drugmaker expects its $700.5 million in cash, equivalents and marketable securities to fund operations through 2030, adding more than two years to its prior target of the second half of 2028. By our math, covering 17 quarters through the end of 2030 implies an average net cash burn of about $41.2 million per quarter.
New. After delivering the initial Phase 2 readout in September 2026, management set 2027 as the target for starting a Phase 3 adjuvant bladder cancer trial, subject to regulatory feedback, and for reporting additional Phase 2 ablative data including the new 70 mg cohort.
Unchanged. The clinical-stage group still expects to report initial Phase 2a/b results for dabogratinib across the 60 mg and 80 mg daily cohorts in low-grade upper tract urothelial carcinoma in 2027, following the first patient's complete response reported in September.
Cut. The readout for the safety sentinel cohort of roughly 25 children moved from the end of the first quarter of 2027 to an unspecified point in 2027 after the safety committee cleared a sixth dose level (0.875 mg/kg). It is the third consecutive quarter management has pushed the timeline out: from second-half 2026, to fourth-quarter 2026, to end of first-quarter 2027, and now to 2027.
❓ Key Questions
What were the efficacy results in the 50 mg cohort?
Prior outlook statements promised initial SURF302 efficacy from more than 20 patients across the 50 mg and 60 mg doses. The release reported response rates for 14 patients on 60 mg and gave no efficacy figures for the 50 mg group.
How long are the bladder cancer complete responses lasting?
Nine of 14 evaluated patients on 60 mg achieved a complete response, including six of eight with a single lesion. Management has not yet shared six-month or 12-month durability data to show whether tumours stay gone after treatment.
When in 2027 will the BEACH301 growth data arrive?
Adding a sixth dose level at 0.875 mg/kg requires six months of follow-up to measure annualized height velocity. Investors need to know whether the readout will wait for the sixth cohort to finish six months of dosing.
How many shares and pre-funded warrants did the offering add?
The September financing raised $400 million in gross proceeds, but the release did not break out the exact number of common shares and pre-funded warrants issued, which will determine the fully diluted share count in the fourth quarter.